Immix Biopharma Receives Tepid Wall Street Reception in IPO Debut

Pat Maio
Pat Maio has held various reporting and editorial management positions over the past 25 years, having specialized in business and government reporting. He has held reporting jobs with the San Diego Union-Tribune, Orange County Register, Dow Jones News and other newspapers in Ohio, West Virginia, Maryland and Washington, D.C.
Immix Biopharma Receives Tepid Wall Street Reception in IPO Debut
Photo by National Cancer Institute on Unsplash

Immix Biopharma Inc., a Santa Monica-based biotechnology company, got slammed in its trading debut this week, losing 27% of its value in its first day of trading on Nasdaq.

On Friday, the tiny biotech’s stock closed at $4 a share, a recovery of about 9% from its previous opening day’s close.


The nine-year-old company, which is known for its tissue-specific therapeutics that aims to help doctors rely less on traditional chemotherapy, was cofounded by Ilya Rachman, a physician at the world renowned Cedars-Sinai Medical Center in Los Angeles.

Immix raised $21 million in its IPO.

Proceeds from the IPO will be used to fund clinical trials for several of its cancer therapeutics that target tumors, colorectal cancer and soft tissue sarcoma. It’s planning several trials of its therapies, or medical treatments, in 2022.

Overall, the company is focusing its research on soft-tissue sarcomas, which are a group of cancers found in blood vessels, fat cells and the lining of joints.

Gabriel Morris, chief financial officer of Immix, did not return phone calls seeking comment on his company’s initial public offering, or IPO, and its tepid reception that it received on Wall Street.

In an email, Morris wrote Friday that the company is in a regulatory and legal “quiet period” which prohibits the company from making any public statements for another 25 days.

In 2020, the early stage growth company with a market capitalization of $26.4 million, reported a loss of $1.1 million. It also reported a loss of $1.6 million in its first nine months of 2021.

In filings with the U.S. Securities and Exchange Commission, Immix says that its competitors include biotech firms like Kymera Therapeutics Inc.; Morphic Holding Inc.; RAPT Therapeutics Inc.; Arena Pharmaceuticals Inc.; Landos Biopharma Inc.; and, Seres Therapeutics Inc.

dot.LA reporter Keerthi Vedantam contributed to this post.

Subscribe to our newsletter to catch every headline.

Cadence

Genies Wants To Help Creators Build ‘Avatar Ecosystems’

Christian Hetrick

Christian Hetrick is dot.LA's Entertainment Tech Reporter. He was formerly a business reporter for the Philadelphia Inquirer and reported on New Jersey politics for the Observer and the Press of Atlantic City.

Genies Wants To Help Creators Build ‘Avatar Ecosystems’

When avatar startup Genies raised $150 million in April, the company released an unusual message to the public: “Farewell.”

The Marina del Rey-based unicorn, which makes cartoon-like avatars for celebrities and aims to “build an avatar for every single person on Earth,” didn’t go under. Rather, Genies announced it would stay quiet for a while to focus on building avatar-creation products.

Genies representatives told dot.LA that the firm is now seeking more creators to try its creation tools for 3D avatars, digital fashion items and virtual experiences. On Thursday, the startup launched a three-week program called DIY Collective, which will mentor and financially support up-and-coming creatives.

Read moreShow less

Here's What To Expect At LA Tech Week

Christian Hetrick

Christian Hetrick is dot.LA's Entertainment Tech Reporter. He was formerly a business reporter for the Philadelphia Inquirer and reported on New Jersey politics for the Observer and the Press of Atlantic City.

Here's What To Expect At LA Tech Week

LA Tech Week—a weeklong showcase of the region’s growing startup ecosystem—is coming this August.

The seven-day series of events, from Aug. 15 through Aug. 21, is a chance for the Los Angeles startup community to network, share insights and pitch themselves to investors. It comes a year after hundreds of people gathered for a similar event that allowed the L.A. tech community—often in the shadow of Silicon Valley—to flex its muscles.

From fireside chats with prominent founders to a panel on aerospace, here are some highlights from the roughly 30 events happening during LA Tech Week, including one hosted by dot.LA.

Read moreShow less
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending